Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Lexeo Therapeutics, Inc. Common Stock logo

Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock Ticker

NASDAQ: LXEO · Healthcare · Biotechnology
$3.31-2.36%
USD · as of 2026-09-28 · market cap $259.9M
Open LXEO in TickrDownload for iPhone

LXEO right now

Down 32% in the last month.
Options expect by Oct 6±10.8%
Options expect by Oct 29±22.3%
IV rank (30-day)19% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full LXEO picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on LXEO
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

LXEO stock facts

Ticker symbolLXEO
ExchangeNASDAQ Global Market
SectorHealthcare
IndustryBiotechnology
Market cap$259.9M
CEOR. Nolan Townsend
Employees63
HeadquartersNew York City, NY, US
IPO date2023-11-03
Websitewww.lexeotx.com

What you can see for LXEO on Tickr

Live LXEO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the LXEO report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Lexeo Therapeutics, Inc. Common Stock?

The ticker symbol for Lexeo Therapeutics, Inc. Common Stock is LXEO, listed on the NASDAQ Global Market.

What is LXEO?

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting…

HomeExploreMarketLists
All pages